NCBiotech: Why North Carolina Biomanufacturing Won’t Run Out of Talent

“It’s an easy move to say, ‘Oh, you’re becoming victims of your own success. Where do I find my talent?’ And I would argue you’re going to find it exactly where you found it before, and there’s plenty of it,” says Bill Bullock.

Bill Bullock is Senior Vice President of Economic and Statewide Development at the North Carolina Biotechnology Center (NCBiotech). He trained as a biochemist and worked at the bench for a California startup before doing an MBA at UNC Chapel Hill. He joined NCBiotech in 2003 to build out its economic development function, and has spent more than two decades bringing life sciences companies to the state.

North Carolina now employs roughly 36,000 people in life sciences manufacturing. Since January 2022, the state has recorded 67 life sciences company expansions and more than 10,000 announced jobs. In the past year alone, AbbVie, Genentech, J&J Innovative Medicine, and Novartis have all announced expansions, and FUJIFILM Biotechnologies opened its Holly Springs biomanufacturing facility. In the latest PharmaSource podcast episode, Bill explains what is drawing manufacturers to North Carolina, how the state keeps its talent pipeline ahead of demand, and where it still needs to catch up.

Why Manufacturers Are Betting on North Carolina Biomanufacturing

Bill gives two main reasons for the state’s pull: labor, and a business climate built for manufacturing. Companies such as Biogen and Pfizer have operated in North Carolina for decades, so new arrivals find an established talent base. The policy environment helps too.

“We’re a pretty business-friendly state. If you look at the tax climate in North Carolina, if you look at the labor policy climate in North Carolina, the affordability of North Carolina, not only in terms of business, but for people moving here or staying here, it’s all very favorable to manufacturing.”

Then outside pressures added to that base. The first gene therapy approval in 2017, global capacity constraints, COVID, and more recently tariffs all pushed multinationals to invest in US manufacturing. Bill says North Carolina was already on their radar when that happened.

“Companies had already been doing it, so we were getting interest from a lot of those companies. Other locations have done well. There’s just a lot of investment going on. You’ve seen investments in Texas, Ohio, Virginia, Georgia, and other places. And I think that’s just a manifestation of the level of investment right now, which is, frankly, unprecedented in the pharma manufacturing space.”

Addressing the Talent Gap

The question Bill hears often is whether there are enough people to staff all this new capacity. He doesn’t expect every project to land in North Carolina. Companies such as Eli Lilly spread sites across locations to manage risk. But he is firmly optimistic about talent.

“I always argue that if you’re going to expand somewhere and need to hire folks, you can only do two things: hire them from another local company or bring them in from somewhere else. Arguably, we have as many biomanufacturing companies in North Carolina as any location on the planet. So in terms of the first piece, yes, you can find them. The second piece is that people are moving to North Carolina. In the Triangle region alone, 100 people a day are moving into the area.”

He admits that if the labor market gets too tight, “it can ratchet wage rates up,” and adds: “But I’ve seen companies manage through that over and over again.” The state also produces around 12,000 students a year in bio-related fields, and is investing at least $230 million in training infrastructure, which Bill calls the largest investment in its community colleges in state history.

How BioWork Turns Manufacturing Workers into Biomanufacturing Talent

As textile, tobacco, and furniture manufacturing moved offshore, North Carolina was left with “a lot of capable talent in the state… who had good manufacturing understanding, training. They just didn’t know life sciences.” NCBiotech’s answer was BioWork, a certificate program now offered at 15 of the state’s 58 community colleges.

“It’s a hundred and thirty-six-hour non-degreed certificate, and students can come in with transferable skills and learn the basis of what GMP means, what it means to work in a regulated environment. What does aseptic mean? What’s an SOP? What does it mean to gown?”

Because the program travels easily, it can follow companies into new regions. Bill points to Eli Lilly’s expansion in Cabarrus County, near Charlotte, an area with plenty of advanced manufacturing but little biomanufacturing:

“Their local community college did not teach BioWork, but we just quickly transferred it… So we just simply scaled up BioWork at Rowan-Cabarrus Community College, and Lilly has done very well in finding employees and running a lot of folks through that BioWork program.”

Building a Collaborative Training Ecosystem

BioWork is one of three training pillars. NC State University’s Biomanufacturing Training and Education Center (BTEC) provides four-year and master’s-level training. North Carolina Central University hosts BRITE. The collaborative that connects them, NC BioImpact, brings in NCBiotech and the trade group NC Life Sciences to adjust curricula as industry needs change.

Bill traces this back to a “very purposeful and intentional strategy that North Carolina needed to pursue to pull itself out as a pretty poor state back in the mid ’50s,” which began with the creation of Research Triangle Park.

“So it’s a lot of different programs, but it’s the connectivity and communication across those programs that I think ultimately are what companies like. We bring those companies together all the time to ask them how things are going and what we need to change. And I think that’s been a large part of why we’ve been so successful so far and why I think we’ll continue to see that success in the future.”

Closing the Supply Chain Gap

Bill is candid that the supplier base has not kept pace with the manufacturers. When he asks companies what else North Carolina needs, “the first topic is always workforce… But right at the top of the list is also supply chain and the idea of getting more suppliers more locally, accessible to our companies.”

There has been some progress. Swiss device maker Ypsomed is coming to Holly Springs, alongside FUJIFILM, Genentech, and Amgen, and Nipro is establishing a site in Greenville, where Thermo Fisher already has a large facility. Bill sees much more to do:

“In as much as we’ve worked really closely with these pharma companies to get them into North Carolina, we need to continue to do that on the supplier side to expand access to those for those companies that are here.”

Pricing pressure, China, tariffs, and the lessons of COVID make the picture harder to read, as covered in PharmaSource’s US pharma reshoring policy timeline. But Bill says the fundamentals stay the same: “We continue to focus on them as we have in the last thirty years, but the parameters for consideration right now are pretty complex.”

Speed to Market Is the Next Frontier for North Carolina Biomanufacturing

North Carolina has strong innovators. It has three R1 universities in the Triangle and five statewide, and life sciences venture funding hit a state record last year. Bill argues that the next step is to link that research more closely to the state’s manufacturing strength. “Everything about our success recently, and really historically, ultimately comes back to speed to market,” he says.

Collaboration is “one of our superpowers,” he adds, “but institutions can be challenging. They’re set up to do fundamental research, train students, and we fully appreciate that.” The aim is to help small companies commercialize faster, and to help large manufacturers draw on universities for technology, not only for hiring.

“In my experience, there’s no magic bullet for this. It’s hard work. You have to have champions who are in roles at our institutions, in government, and in industry to have an appreciation for the desire to go do that, and you have to create mechanisms for it to happen.”

With new academic leadership and automation changing both the work and the skills it requires, Bill believes the state is at an inflection point. His guiding principle is “safety and speed to market.”